Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Services Industry Analysis

UpdatedJan 03, 2026
DataAggregated Company Financials
Companies163
  • 7D0.5%
  • 3M-2.6%
  • 1Y-9.4%
  • YTD0%

In the last week, Healthcare Services has been flat. As for the longer term, the industry has declined 9.4% in the last year. Earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the U.S. Healthcare Services Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 03 Jan 2026US$897.2bUS$2.1tUS$34.8b22.2x25.8x0.4x
Mon, 01 Dec 2025US$912.6bUS$2.1tUS$34.8b22.7x26.2x0.4x
Wed, 29 Oct 2025US$944.6bUS$2.1tUS$49.4b21.7x19.1x0.4x
Fri, 26 Sep 2025US$906.9bUS$2.1tUS$49.3b20.7x18.4x0.4x
Sun, 24 Aug 2025US$853.9bUS$2.1tUS$49.3b21.3x17.3x0.4x
Tue, 22 Jul 2025US$788.0bUS$2.1tUS$52.2b20.7x15.1x0.4x
Thu, 19 Jun 2025US$876.1bUS$2.1tUS$52.7b21.8x16.6x0.4x
Sat, 17 May 2025US$839.6bUS$2.1tUS$52.4b21.5x16x0.4x
Mon, 14 Apr 2025US$1.1tUS$1.7tUS$41.8b23.2x26.5x0.7x
Wed, 12 Mar 2025US$986.9bUS$1.7tUS$41.4b23.9x23.8x0.6x
Fri, 07 Feb 2025US$1.0tUS$1.7tUS$41.5b23.6x25.3x0.6x
Sun, 05 Jan 2025US$1.0tUS$2.0tUS$42.3b23.3x24.1x0.5x
Tue, 03 Dec 2024US$1.2tUS$2.0tUS$41.4b24.6x28.3x0.6x
Thu, 31 Oct 2024US$1.1tUS$1.9tUS$44.1b24.2x25.4x0.6x
Sat, 28 Sep 2024US$1.2tUS$1.9tUS$43.3b25.8x27.5x0.6x
Mon, 26 Aug 2024US$1.2tUS$1.9tUS$43.3b26.7x28.1x0.6x
Wed, 24 Jul 2024US$1.2tUS$1.9tUS$42.6b27.3x27x0.6x
Fri, 21 Jun 2024US$1.1tUS$1.9tUS$43.4b25.1x24.9x0.6x
Sun, 19 May 2024US$1.1tUS$1.9tUS$43.5b26.6x25.9x0.6x
Tue, 16 Apr 2024US$1.0tUS$1.8tUS$49.7b24.9x21x0.6x
Thu, 14 Mar 2024US$1.1tUS$1.8tUS$50.1b24.2x22.3x0.6x
Sat, 10 Feb 2024US$1.1tUS$1.8tUS$50.4b22.5x22.6x0.6x
Mon, 08 Jan 2024US$1.2tUS$1.8tUS$50.1b23.9x23.5x0.7x
Wed, 06 Dec 2023US$1.2tUS$1.8tUS$51.1b23.1x22.6x0.6x
Fri, 03 Nov 2023US$1.1tUS$1.8tUS$50.8b21.6x22.3x0.6x
Sun, 01 Oct 2023US$1.1tUS$1.8tUS$46.8b22.2x23.5x0.6x
Tue, 29 Aug 2023US$1.1tUS$1.8tUS$46.7b21.9x23.4x0.6x
Thu, 27 Jul 2023US$1.1tUS$1.7tUS$46.7b23.6x24.4x0.7x
Sat, 24 Jun 2023US$1.1tUS$1.7tUS$45.8b23x23.8x0.6x
Mon, 22 May 2023US$1.1tUS$1.7tUS$45.7b22x23.8x0.6x
Wed, 19 Apr 2023US$1.1tUS$1.4tUS$44.1b23.2x24.9x0.8x
Fri, 17 Mar 2023US$1.1tUS$1.4tUS$44.0b21.9x23.9x0.7x
Sun, 12 Feb 2023US$1.1tUS$1.4tUS$44.2b22.2x25.5x0.8x
Tue, 10 Jan 2023US$1.1tUS$1.4tUS$44.4b21x25.2x0.8x
Price to Earnings Ratio

25.2x


Total Market Cap: US$1.1tTotal Earnings: US$44.4bTotal Revenue: US$1.4tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Services Industry Price to Earnings3Y Average 23.4x202420252026
Current Industry PE
  • Investors are optimistic on the American Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 25.8x which is higher than its 3-year average PE of 23.4x.
  • The industry is trading close to its 3-year average PS ratio of 0.58x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 7.7% per year over the last three years.
  • Meanwhile revenues for these companies have grown 15% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.05%
Healthcare-0.81%
Healthcare Services0.54%
Managed Healthcare1.57%
Healthcare Services-0.21%
Healthcare Distributors-0.36%
Healthcare Facilities-1.75%
Industry PE
  • Investors are most optimistic about the Healthcare Distributors industry, which is trading close to its 3-year average PE ratio of 39.3x.
    • Analysts are expecting annual earnings growth of 17.2%, which is higher than its past year's earnings growth of 13.7% per year.
  • Investors are most pessimistic about the Healthcare Facilities industry, which is trading below its 3-year average of 20.9x.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 27% over the next 5 years.
  • This is better than its past earnings growth rate of 16% per year.
  • In contrast, the Healthcare Facilities industry is expected to see its earnings grow by 13% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
UNH UnitedHealth GroupUS$336.401.4%
+US$4.1b		-34.4%PE17.3x
ELV Elevance HealthUS$354.251.2%
+US$971.2m		-4.7%PE14.2x
MOH Molina HealthcareUS$178.468.3%
+US$700.1m		-39.4%PE10.4x
CI Cigna GroupUS$279.120.9%
+US$697.2m		-0.6%PE12.1x
HUM HumanaUS$264.482.2%
+US$679.5m		0.8%PE24.6x

Latest News

HIMS
US$33.41
Hims & Hers Health
7D
-2.6%
1Y
25.5%

Hims & Hers Health (NYSE:HIMS) Seems To Use Debt Rather Sparingly

Jan 03
Hims & Hers Health (NYSE:HIMS) Seems To Use Debt Rather Sparingly
CNC
US$41.78
Centene
7D
3.1%
1Y
-32.0%
HCA
US$470.39
HCA Healthcare
7D
-1.4%
1Y
58.5%

Investors Continue Waiting On Sidelines For HCA Healthcare, Inc. (NYSE:HCA)

Jan 02
Investors Continue Waiting On Sidelines For HCA Healthcare, Inc. (NYSE:HCA)
UHS
US$219.88
Universal Health Services
7D
-3.4%
1Y
22.9%

With EPS Growth And More, Universal Health Services (NYSE:UHS) Makes An Interesting Case

Jan 02
With EPS Growth And More, Universal Health Services (NYSE:UHS) Makes An Interesting Case
HQY
US$91.07
HealthEquity
7D
-2.6%
1Y
-6.6%

Here's Why We Think HealthEquity (NASDAQ:HQY) Might Deserve Your Attention Today

Jan 01
Here's Why We Think HealthEquity (NASDAQ:HQY) Might Deserve Your Attention Today
ALHC
US$20.22
Alignment Healthcare
7D
7.7%
1Y
72.8%
MOH
US$178.46
Molina Healthcare
7D
8.3%
1Y
-39.4%
CAH
US$205.72
Cardinal Health
7D
-1.2%
1Y
72.4%

CAH: Future EPS Momentum And Policy Shifts Will Define Risk Reward Balance

Analysts have nudged their average price targets for Cardinal Health higher into the low $210s, citing stronger than expected EPS momentum, sustained core Pharma outperformance, and incremental upside from the Solaris acquisition and broader industry demand. Analyst Commentary Recent Street research has tilted decisively positive on Cardinal Health, with multiple firms lifting price targets into the $210 to $220 range as they recalibrate earnings and valuation assumptions following stronger than expected results and the Solaris acquisition.
HUM
US$264.48
Humana
7D
2.2%
1Y
0.8%
CVS
US$80.13
CVS Health
7D
0.7%
1Y
75.1%

CVS: Medicare Advantage Margin Recovery Is Expected To Drive Earnings Momentum From 2026

Analysts have modestly raised their price target on CVS Health, with our fair value estimate increasing from approximately $92.44 to $94.33. This reflects growing confidence in earnings visibility, margin recovery in Medicare Advantage, and supportive recent EPS revisions despite mixed near term trends.
ELV
US$354.25
Elevance Health
7D
1.2%
1Y
-4.7%
MCK
US$823.44
McKesson
7D
-0.6%
1Y
42.6%
COR
US$338.87
Cencora
7D
-0.6%
1Y
47.8%
UNH
US$336.40
UnitedHealth Group
7D
1.4%
1Y
-34.4%

UNH: Margin Recovery And Policy Risks Will Shape Earnings Trajectory

Analysts have raised their fair value estimate for UnitedHealth Group from $198.00 to approximately $304.61 as they factor in a sector wide margin recovery in Medicare Advantage and Medicaid, improved pricing discipline at Optum Health, and a higher forward price to earnings multiple reflecting expectations for significant EPS growth in the coming years. Analyst Commentary Recent Street research on UnitedHealth Group reflects a generally constructive outlook on earnings recovery and valuation, but with a growing emphasis on execution risk around Medicare Advantage repricing, regulatory changes, and the pace of Optum margin normalization.
CI
US$279.12
Cigna Group
7D
0.9%
1Y
-0.6%

CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum

Narrative Update on Cigna Group Analysts have slightly lowered their price target on Cigna Group by approximately $2 to around $326 per share, reflecting modest tweaks to assumptions on long term growth, profitability, and valuation multiples, while maintaining a broadly constructive outlook. What's in the News Cigna Group reported that between July 1 and September 30, 2025, it repurchased no additional shares under its existing authorization, having already completed the buyback of about 133.5 million shares, or 41.09% of shares outstanding, for roughly $34.44 billion since the program was announced in December 2018 (company filing).
DGX
US$173.79
Quest Diagnostics
7D
-1.2%
1Y
14.4%

DGX: Future Lab Partnerships And Testing Pipeline Will Support Balanced Outlook

Analysts have nudged their price targets on Quest Diagnostics higher by between $5 and $25 per share, citing solid Q3 outperformance, raised guidance, and confidence in organic growth and future testing catalysts. Analyst Commentary Street research following the Q3 print highlights a generally constructive stance on Quest Diagnostics, with most price target increases framed around stronger than expected fundamentals and improving visibility into growth drivers over the next two years.